查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889520

2025年下一代癌症診斷全球市場報告

Next Generation Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，下一代癌症診斷市場發展迅速，預計將從2024年的127.1億美元成長到2025年的144億美元，複合年成長率達13.3%。過去幾年的成長可歸因於全球癌症發病率的上升、分子診斷技術的日益普及、對癌症早期檢測需求的成長、醫療基礎設施的擴張以及基於生物標記的篩檢的日益普及。

預計未來幾年，下一代癌症診斷市場將快速成長，到2029年市場規模將達到234.5億美元，複合年成長率（CAGR）為13.0%。預測期內的成長預計將受到以下因素的推動：對精準腫瘤學的日益重視、對微創診斷技術需求的成長、人工智慧和數位工具在癌症檢測中的應用日益廣泛、基因組檢測服務的擴展以及政府對癌症研究投入的增加。預測期內的關鍵趨勢包括：非侵入性診斷檢測方法的開發、雲端基礎的數據分析的整合、基於奈米技術的生物感測器的創新、真實世界數據和臨床數據的整合以及機器人和自動化技術的整合。

未來幾年，對個人化醫療日益成長的需求預計將推動下一代癌症診斷市場的擴張。個人化醫療是指根據個人的基因組成、生活方式和環境量身定做治療方法，以確保每位患者都能獲得最有效的治療方法。這種需求的驅動力源於慢性病和罕見患者病率的不斷上升，這些疾病需要針對特定患者進行標靶治療，以獲得更好的臨床療效。下一代癌症診斷技術透過提供精準的分子訊息，為個人化醫療提供支持，從而根據患者獨特的基因和腫瘤特徵制定個人化的治療策略。例如，根據美國非營利組織「個人化醫療聯盟」（Personalized Medicine Coalition）2024年2月發布的報告，美國食品藥物管理局（FDA）預計將在2023年核准16種針對罕見疾病患者的新型個人化療法，較2022年的6種顯著增加。因此，對個人化醫療日益成長的需求正在推動下一代癌症診斷市場的成長。

新一代癌症診斷市場的主要企業正在開發創新解決方案，例如人工智慧 (AI) 驅動的多模態診斷平台，以實現早期檢測、個人化治療和改進臨床決策。這些 AI 驅動的多模態平台整合並分析包括基因組、蛋白質組、影像和臨床資訊在內的多種生物學數據，從而實現更精準、更個人化的癌症檢測和診斷。例如，2025 年 4 月，總部位於印度的精準腫瘤學公司 OneCell Diagnostics Pvt Ltd. 推出了 OncoIncytes，多模態癌症診斷平台。該平台整合了循環腫瘤 DNA、單細胞循環性腫瘤細胞、RNA 數據以及 150 種蛋白質的單細胞層面詳細圖譜。 OncoIncytes 利用 AI 和機器學習驅動的包含 1080 個基因的 panel，提供高度靈敏和特異性的分析結果，可以改善臨床試驗結果，尤其是在早期研究和抗體藥物複合體(ADC) 開發方面。該平台透過非侵入性、即時和可擴展的診斷技術，支援個人化癌症檢測、治療監測和藥物開發，所有這些技術都可透過 OneCell 的專有 iDiscover 應用程式提供給 CLIA 認證的檢查室。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球下一代癌症診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球下一代癌症診斷市場：成長率分析
  • 全球下一代癌症診斷市場表現：規模與成長，2019-2024年
  • 全球下一代癌症診斷市場預測：規模和成長，2024-2029年，2034年預測
  • 全球下一代癌症診斷市場：潛在市場規模 (TAM)

第6章 市場細分

  • 全球下一代癌症診斷市場：依技術、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 次世代定序（NGS）
  • Q聚合酵素鏈鎖反應與多重反應
  • 晶片實驗室（LOAC）和逆轉錄聚合酵素鏈鎖反應（RT-PCR）
  • 循環腫瘤DNA檢測
  • 蛋白質微陣列
  • 去氧核糖核酸微陣列
  • 其他多組體學平台
  • 全球下一代癌症診斷市場：按癌症類型、表現和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 全球下一代癌症診斷市場：依功能、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 治療監測
  • 伴隨診斷
  • 預後診斷
  • 癌症篩檢
  • 風險分析
  • 全球下一代癌症診斷市場：按應用、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 生物標記開發
  • 循環性腫瘤細胞（CTC）分析
  • 蛋白質體學分析
  • 表觀遺傳分析
  • 基因分析
  • 全球下一代癌症診斷市場：依最終用戶、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 醫院和診所
  • 診斷檢查室
  • 研究和學術機構
  • 製藥和生物技術公司
  • 居家醫療環境
  • 全球新一代癌症診斷市場：次世代定序細分，依類型、效能與預測（2019-2024年、2024-2029年預測、2034年預測）。
  • 全基因測序
  • 標靶基因定序
  • EXOME定序
  • 轉錄定序
  • 全球下一代癌症診斷市場：按聚合酵素鏈鎖反應和多重檢測技術細分，按類型分類，實際值和預測值，2019-2024年，2024-2029年預測值，2034年預測值
  • 定量聚合酵素鏈鎖反應
  • 數位聚合酵素鏈鎖反應
  • 多重聚合酵素鏈鎖反應
  • 逆轉錄聚合酵素鏈鎖反應
  • 全球下一代癌症診斷市場：按晶片實驗室和逆轉錄-聚合酵素鏈鎖反應細分，按類型、性能和預測（2019-2024年、2024-2029年預測、2034年預測）
  • 微流體晶片檢測
  • 整合式逆轉錄聚合酵素鏈鎖反應晶片
  • 照護現場實驗室晶片設備
  • 高通量晶片實驗室系統
  • 全球下一代癌症診斷市場：按循環腫瘤DNA檢測方法細分，按類型、性能和預測（2019-2024年、2024-2029年預測、2034年預測）。
  • 單基因循環腫瘤去氧核糖核酸檢測
  • 多基因循環腫瘤去氧核糖核酸檢測
  • 數位液滴循環腫瘤DNA檢測
  • 次世代定序循環腫瘤DNA檢測
  • 全球下一代癌症診斷市場：按蛋白質微陣列、類型、性能和預測進行細分，2019-2024年、2024-2029年預測、2034年預測
  • 分析型蛋白質微陣列
  • 功能性蛋白質微陣列
  • 反相蛋白質微陣列
  • 基於抗體的蛋白質微陣列
  • 全球下一代癌症診斷市場：去氧核糖核酸微陣列細分，按類型、性能和預測（2019-2024年、2024-2029年預測、2034年預測）
  • 基因表現去氧核糖核酸微陣列
  • 單核苷酸基因型鑒定去氧核糖核酸微陣列
  • 比較基因組雜合反應去氧核糖核酸微陣列
  • 甲基化去氧核糖核酸微陣列
  • 全球下一代癌症診斷市場：按其他多組體學平台細分，按類型、性能和預測（2019-2024年、2024-2029年預測、2034年預測）。
  • 代謝體學平台
  • 表觀基因平台
  • 轉錄組學平台
  • 整合多組體學系統

第7章 區域和國家分析

  • 全球下一代癌症診斷市場：按地區、績效和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 全球下一代癌症診斷市場：按國家、績效和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 下一代癌症診斷市場：競爭格局
  • 下一代癌症診斷市場：公司概況
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Danaher Corporation
  • Koninklijke Philips NV
  • General Electric Company
  • Becton, Dickinson and Company
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • Exact Sciences Corporation
  • QIAGEN NV
  • Almac Group Ltd.
  • Natera Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Inc.
  • Guardant Health Inc.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年下一代癌症診斷市場：提供新機會的國家
  • 2029年下一代癌症診斷市場：蘊藏新機會的細分市場
  • 下一代癌症診斷市場（2029 年）：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r40068

Next generation cancer diagnostics refers to advanced diagnostic technologies that enable precise detection, characterization, and monitoring of cancer at the molecular and genetic levels. These diagnostics use cutting-edge tools such as genomics, proteomics, and liquid biopsy to support early detection, personalized treatment planning, and improved patient outcomes.

The main technologies used in next generation cancer diagnostics include next-generation sequencing (NGS), q-polymerase chain reaction and multiplexing, lab-on-a-chip (LOAC) and reverse transcriptase-polymerase chain reaction (RT-PCR), circulating tumor deoxyribonucleic acid (ctDNA) assays, protein microarrays, deoxyribonucleic acid microarrays, and others. Next-generation sequencing (NGS) is a high-throughput DNA sequencing method that enables rapid, simultaneous sequencing of millions of DNA fragments, allowing comprehensive analysis of genomes, transcriptomes, and genetic variations. These technologies target various cancer types, including lung cancer, breast cancer, colorectal cancer, and cervical cancer. Their functions include therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. They are applied in biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis, and serve end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, pharmaceutical and biotechnology companies, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The next generation cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides next generation cancer diagnostics market statistics, including next generation cancer diagnostics industry global market size, regional shares, competitors with a next generation cancer diagnostics market share, detailed next generation cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next generation cancer diagnostics industry. This next generation cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next generation cancer diagnostics market size has grown rapidly in recent years. It will grow from $12.71 billion in 2024 to $14.40 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period resulted from the increasing prevalence of cancer worldwide, growing adoption of molecular diagnostics, rising demand for early cancer detection, expansion of healthcare infrastructure, and greater use of biomarker-based screening.

The next generation cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $23.45 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period will be driven by a rising focus on precision oncology, increasing demand for minimally invasive diagnostic techniques, growing adoption of artificial intelligence and digital tools in cancer detection, expansion of genomic testing services, and increasing government funding for cancer research. Major trends in the forecast period include the development of non-invasive diagnostic assays, integration of cloud-based data analytics, innovations in nanotechnology-based biosensors, incorporation of real-world evidence and clinical data, and the integration of robotics and automation.

The rising demand for personalized medicines is expected to drive the expansion of the next-generation cancer diagnostics market in the coming years. Personalized medicines are treatments tailored to an individual's genetic makeup, lifestyle, and environment to ensure the most effective therapy for each patient. This demand is fueled by the growing prevalence of chronic and rare diseases, which require targeted, patient-specific treatments for better clinical outcomes. Next-generation cancer diagnostics support personalized medicine by providing precise molecular insights that inform customized treatment strategies based on a patient's unique genetic and tumor profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Consequently, the rising demand for personalized medicines is driving the growth of the next-generation cancer diagnostics market.

Key players in the next-generation cancer diagnostics market are developing innovative solutions such as artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized therapy, and clinical decision-making. These AI-powered multi-modal platforms integrate and analyze diverse biological data-including genomic, proteomic, imaging, and clinical information-to deliver more accurate and individualized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform designed for precision oncology. The platform combines circulating tumor DNA, single-cell circulating tumor cells, RNA data, and detailed protein profiles of 150 proteins at the single-cell level. Using a 1,080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to improve clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell's proprietary iDiscover application from a CLIA-certified laboratory.

In June 2023, Quest Diagnostics Inc., a US-based healthcare diagnostics company, acquired Haystack Oncology for an undisclosed amount. This acquisition aimed to strengthen Quest Diagnostics' capabilities in the rapidly growing minimal residual disease (MRD) liquid biopsy market. Haystack Oncology Inc., a US-based firm, provides next-generation cancer diagnostics through its tumor-informed MRD test, Haystack MRD.

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

North America was the largest region in the next generation cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next generation cancer diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation cancer diagnostics market consists of revenues earned by entities by providing services such as genomic and molecular profiling, liquid biopsy testing, next-generation sequencing (NGS) services, companion diagnostics development, and bioinformatics and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation cancer diagnostics market also includes sales of gene panels, single-cell analysis systems, nanotechnology-based biosensors, molecular imaging agents, and exosome isolation kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Next-Generation Sequencing (NGS); QPolymerase Chain Reaction And Multiplexing; Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR); Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays; Protein Microarrays; Deoxyribonucleic Acid Microarrays; Other Multi-Omics Platforms
  • 2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Cervical Cancer
  • 3) By Function: Therapeutic Monitoring; Companion Diagnostics; Prognostics; Cancer Screening; Risk Analysis
  • 4) By Application: Biomarker Development; Circulating Tumor Cell (CTC) Analysis; Proteomic Analysis; Epigenetic Analysis; Genetic Analysis
  • 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Pharmaceutical And Biotechnology Companies; Home Care Settings
  • Subsegments:
  • 1) By Next-Generation Sequencing: Whole Genome Sequencing; Targeted Gene Sequencing; Exome Sequencing; Transcriptome Sequencing
  • 2) By Quantitative Polymerase Chain Reaction And Multiplexing: Quantitative Polymerase Chain Reaction; Digital Polymerase Chain Reaction; Multiplex Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction
  • 3) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays; Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips; Point-of-Care Lab-On-A-Chip Devices; High-Throughput Lab-On-A-Chip Systems
  • 4) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays; Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels; Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays; Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
  • 5) By Protein Microarrays: Analytical Protein Microarrays; Functional Protein Microarrays; Reverse Phase Protein Microarrays; Antibody-Based Protein Microarrays
  • 6) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays; Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays; Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays; Methylation Deoxyribonucleic Acid Microarrays
  • 7) By Other Multi-Omics Platforms: Metabolomics Platforms; Epigenomics Platforms; Transcriptomics Platforms; Integrated Multi-Omics Systems
  • Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG; Danaher Corporation; Koninklijke Philips N.V.; General Electric Company; Becton, Dickinson and Company; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Exact Sciences Corporation; QIAGEN N.V.; Almac Group Ltd.; Natera Inc.; Myriad Genetics Inc.; NeoGenomics Inc.; Guardant Health Inc.; Freenome Holdings Inc.; Personalis Inc.; Burning Rock Biotech Limited.; SOPHiA GENETICS S.A.; Singlera Genomics Co. Ltd.
  • Countries:

Table of Contents

1. Executive Summary

2. Next Generation Cancer Diagnostics Market Characteristics

3. Next Generation Cancer Diagnostics Market Trends And Strategies

4. Next Generation Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Next Generation Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Next Generation Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Next Generation Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Next Generation Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Next Generation Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Next Generation Cancer Diagnostics Total Addressable Market (TAM)

6. Next Generation Cancer Diagnostics Market Segmentation

  • 6.1. Global Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing (NGS)
  • QPolymerase Chain Reaction And Multiplexing
  • Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays
  • Protein Microarrays
  • Deoxyribonucleic Acid Microarrays
  • Other Multi-Omics Platforms
  • 6.2. Global Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • 6.3. Global Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis
  • 6.4. Global Next Generation Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biomarker Development
  • Circulating Tumor Cell (CTC) Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • 6.5. Global Next Generation Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Research And Academic Institutions
  • Pharmaceutical And Biotechnology Companies
  • Home Care Settings
  • 6.6. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing
  • Targeted Gene Sequencing
  • Exome Sequencing
  • Transcriptome Sequencing
  • 6.7. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Quantitative Polymerase Chain Reaction And Multiplexing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Quantitative Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
  • Multiplex Polymerase Chain Reaction
  • Reverse Transcription Polymerase Chain Reaction
  • 6.8. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Microfluidic Chip Assays
  • Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips
  • Point-of-Care Lab-On-A-Chip Devices
  • High-Throughput Lab-On-A-Chip Systems
  • 6.9. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Circulating Tumor Deoxyribonucleic Acid Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays
  • Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels
  • Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays
  • Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
  • 6.10. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Protein Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Analytical Protein Microarrays
  • Functional Protein Microarrays
  • Reverse Phase Protein Microarrays
  • Antibody-Based Protein Microarrays
  • 6.11. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Deoxyribonucleic Acid Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Expression Deoxyribonucleic Acid Microarrays
  • Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays
  • Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays
  • Methylation Deoxyribonucleic Acid Microarrays
  • 6.12. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Other Multi-Omics Platforms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metabolomics Platforms
  • Epigenomics Platforms
  • Transcriptomics Platforms
  • Integrated Multi-Omics Systems

7. Next Generation Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Next Generation Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Next Generation Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Cancer Diagnostics Market

  • 8.1. Asia-Pacific Next Generation Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Cancer Diagnostics Market

  • 9.1. China Next Generation Cancer Diagnostics Market Overview
  • 9.2. China Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Cancer Diagnostics Market

  • 10.1. India Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Cancer Diagnostics Market

  • 11.1. Japan Next Generation Cancer Diagnostics Market Overview
  • 11.2. Japan Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Cancer Diagnostics Market

  • 12.1. Australia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Cancer Diagnostics Market

  • 13.1. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Cancer Diagnostics Market

  • 14.1. South Korea Next Generation Cancer Diagnostics Market Overview
  • 14.2. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Cancer Diagnostics Market

  • 15.1. Western Europe Next Generation Cancer Diagnostics Market Overview
  • 15.2. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Cancer Diagnostics Market

  • 16.1. UK Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Cancer Diagnostics Market

  • 17.1. Germany Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Cancer Diagnostics Market

  • 18.1. France Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Cancer Diagnostics Market

  • 19.1. Italy Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Cancer Diagnostics Market

  • 20.1. Spain Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Cancer Diagnostics Market

  • 21.1. Eastern Europe Next Generation Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Cancer Diagnostics Market

  • 22.1. Russia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Cancer Diagnostics Market

  • 23.1. North America Next Generation Cancer Diagnostics Market Overview
  • 23.2. North America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Cancer Diagnostics Market

  • 24.1. USA Next Generation Cancer Diagnostics Market Overview
  • 24.2. USA Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Cancer Diagnostics Market

  • 25.1. Canada Next Generation Cancer Diagnostics Market Overview
  • 25.2. Canada Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Cancer Diagnostics Market

  • 26.1. South America Next Generation Cancer Diagnostics Market Overview
  • 26.2. South America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Cancer Diagnostics Market

  • 27.1. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Cancer Diagnostics Market

  • 28.1. Middle East Next Generation Cancer Diagnostics Market Overview
  • 28.2. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Cancer Diagnostics Market

  • 29.1. Africa Next Generation Cancer Diagnostics Market Overview
  • 29.2. Africa Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Next Generation Cancer Diagnostics Market Competitive Landscape
  • 30.2. Next Generation Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Danaher Corporation
  • 31.2. Koninklijke Philips N.V.
  • 31.3. General Electric Company
  • 31.4. Becton, Dickinson and Company
  • 31.5. Agilent Technologies Inc.
  • 31.6. Illumina Inc.
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories Inc.
  • 31.9. Exact Sciences Corporation
  • 31.10. QIAGEN N.V.
  • 31.11. Almac Group Ltd.
  • 31.12. Natera Inc.
  • 31.13. Myriad Genetics Inc.
  • 31.14. NeoGenomics Inc.
  • 31.15. Guardant Health Inc.

32. Global Next Generation Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Cancer Diagnostics Market

34. Recent Developments In The Next Generation Cancer Diagnostics Market

35. Next Generation Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Next Generation Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Next Generation Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Next Generation Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer